GLP-1 side effect symptoms

Nausea on GLP-1 medications

30-50%in pivotal trials

Nausea is the most common GLP-1 side effect. It peaks in the first 4-8 weeks of treatment, typically after each dose increase, and resolves as the body adapts to delayed gastric emptying.

Diarrhea on GLP-1 medications

10-15%in pivotal trials

Diarrhea affects ~10-15% of GLP-1 patients during initial titration. Usually self-limited and resolves within 4-8 weeks. Hydration is the primary management concern.

Constipation on GLP-1 medications

7-11%in pivotal trials

Constipation affects ~7-11% of GLP-1 patients. Result of slowed gastric/intestinal motility + reduced food intake. Usually responds well to hydration + fiber + activity.

Fatigue on GLP-1 medications

5-11%in pivotal trials

Fatigue affects ~5-11% of GLP-1 patients. Usually result of reduced calorie intake during early titration + underlying GI side effects + body adapting to weight loss.

Headache on GLP-1 medications

10-14%in pivotal trials

Headache affects ~10-14% of GLP-1 patients during titration. Often dehydration-driven or related to dropping blood-sugar levels in non-diabetic patients.

Hair loss on GLP-1 medications

3-7%in pivotal trials

Hair shedding affects ~3-7% of GLP-1 patients. Almost always telogen effluvium (stress-related shedding from rapid weight loss), NOT permanent hair loss. Resolves within 6-12 months.

Gallbladder issues on GLP-1 medications

6%in pivotal trials

Gallbladder disease (gallstones, cholecystitis) affects ~1.5-2.6% of GLP-1 patients in trials. Risk is highest during rapid weight loss in the first 6-12 months.

Mood changes on GLP-1 medications

FDA conducted post-marketing surveillance on potential suicidal ideation signals (2023-2024); no causal link confirmed. Some patients report mild mood/anxiety changes, often resolving with weight stabilization.

Dizziness on GLP-1 medications

3-8%in pivotal trials

Dizziness on GLP-1 medications usually reflects dehydration or hypoglycemia (if combined with insulin/sulfonylurea), not a direct drug effect. Most cases resolve with better fluid intake and meal timing.

Dry mouth on GLP-1 medications

3-5%in pivotal trials

Dry mouth (xerostomia) affects a small share of GLP-1 patients, mostly during titration. Usually caused by reduced fluid intake, not direct salivary effects.

Brain fog on GLP-1 medications

5-8%in pivotal trials

Cognitive slowness or "brain fog" is reported by a subset of GLP-1 patients, most commonly during titration. Usually traceable to undereating, dehydration, or sleep disruption — not a direct neurologic effect.

Heart palpitations on GLP-1 medications

15-20%in pivotal trials

Mild heart-rate increase (5-10 bpm) is documented across the GLP-1 class. Most patients adapt; persistent palpitations or rates above 100 bpm at rest warrant evaluation.

Increased thirst on GLP-1 medications

10-15%in pivotal trials

Polydipsia (increased thirst) on GLP-1s usually reflects insufficient water intake catching up — patients who weren't drinking enough notice thirst as their body recalibrates.

Taste changes on GLP-1 medications

2-5%in pivotal trials

Some patients report metallic, sour, or muted taste during early titration. Usually transient — resolves within 4-8 weeks of stable dose. Dysgeusia rarely persists.

Sleep changes on GLP-1 medications

8-15%in pivotal trials

GLP-1 medications can affect sleep through multiple paths: delayed gastric emptying disrupts late-night digestion; reduced appetite changes eating schedules; weight loss can improve or worsen sleep apnea. Insomnia and vivid dreams are both reported.

Eye irritation on GLP-1 medications

3-8%in pivotal trials

Mild dry-eye symptoms can occur during GLP-1 therapy, usually due to systemic dehydration. Recent FDA labels added warnings for NAION (rare optic-nerve event) — distinct from common dry-eye.

Joint pain on GLP-1 medications

2-5%in pivotal trials

Mild joint discomfort is occasionally reported on GLP-1s, typically appearing during rapid weight loss phases. Most often reflects lean-mass loss + biomechanical adjustment to changing body composition, not a direct drug effect.

Back pain on GLP-1 medications

3-7%in pivotal trials

Back pain on GLP-1s typically reflects biomechanical changes from rapid weight loss or shifted activity patterns. Pre-existing back conditions may worsen during initial weight loss phases before stabilizing.

Cold intolerance on GLP-1 medications

10-20%in pivotal trials

Feeling cold more easily on GLP-1 medications is commonly reported during weight loss — reflects reduced metabolic rate from lower body mass + thermogenic adaptation, not a direct drug effect.

Dry skin on GLP-1 medications

8-15%in pivotal trials

Dry skin during GLP-1 therapy typically reflects dehydration + reduced food intake (lower water from food). Significant weight loss can also cause skin laxity that feels drier.

Menstrual changes on GLP-1 medications

15-25%in pivotal trials

Significant weight loss on GLP-1s often improves menstrual irregularity, particularly in PCOS or obesity-related anovulation. Some patients also notice cycle changes during titration weeks — usually transient.

Body temperature changes on GLP-1 medications

8-15%in pivotal trials

Some patients on GLP-1s report feeling either colder or warmer than usual. Most reflect metabolic adaptation to weight loss. Persistent thermoregulation issues may signal thyroid involvement.

Blood pressure changes on GLP-1 medications

20-30%in pivotal trials

GLP-1 medications typically lower blood pressure by 3-5 mmHg through weight loss + direct effects. Patients on antihypertensives may experience hypotension and require dose reduction.

Reduced food cravings on GLP-1 medications

60-80%in pivotal trials

Reduced food cravings (often called "food noise quieting") is a hallmark GLP-1 effect — not technically a side effect but a desired pharmacologic outcome. Patients describe intrusive food thoughts dramatically decreasing.